- Case report
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Daptomycin as a possible new treatment option for surgical management of Methicillin-Resistant Staphylococcus aureus sternal wound infection after cardiac surgery
- Aron F Popov†1Email author,
- Jan D Schmitto†1, 2,
- Theodor Tirilomis1,
- Christian Bireta1,
- Kasim O Coskun1,
- Suyog A Mokashi2,
- Alexander Emmert1,
- Martin Friedrich1,
- Christoph H Wiese3 and
- Friedrich A Schoendube1
© Popov et al; licensee BioMed Central Ltd. 2010
Received: 10 May 2010
Accepted: 6 August 2010
Published: 6 August 2010
We present a case of a 77-year old female who had undergone a coronary artery bypass grafting with an aortic valve replacement and developed three month later a Methicillin-Resistant Staphylococcus aureus (MRSA) sternal wound infection which was successful treated with Daptomycin combined with vacuum-assisted closure (VAC).
Sternal wound infection is a severe complication in cardiac surgery despite continuing efforts to improve perioperative conditions. This complication is often associated with significant morbidity and mortality rates of up to 45% , with prolonged hospitalization  and additional surgical procedures, as well as prolonged antibiotic therapy and its inherent high costs . The most common conventional treatments involve surgical revision, open dressing, closed mediastinal irrigation, debridement, complete sternectomy, or reconstruction with omental or muscleflaps . With the increase of MRSA infection, the accompanying antibiotic therapy has received more attention for treatment of sternal wound infections after cardiac surgery.
A 77-year-old female was admitted with coronary artery disease and severe aortic stenosis to the Department of Cardiac Surgery of the University Hospital of Goettingen, Germany in July of 2007. A coronary artery bypass grafting (left anterior descending artery was revascularized by the left internal mammarian artery) and an aortic valve replacement (Cryolife O'Brien® 23 mm, biological) were performed. After an uneventful operation and postoperative course, the patient was discharged home. Three month after discharge, at the initial postoperative visit, physical examination revealed an unstable sternum with purulent drainage (MRSA-positive) from the distal portion of the incision. Subsequently, the patient was hospitalized and started on wide broad spectrum antibiotics (Clindamycin and Rifampicin) in combination with local antiseptic washings. She was urgently taken to the operating room for wound debridement. Once the incision was reopened, frank pus was noted. The wound was irrigated and the sternum was realigned. Her general condition recovered and two months after the operation, the patient was discharged home.
One month following this, the patient returned with purulent drainage forming in the distal wound, necessitating hospital readmission with intravenous antibiotics (Vancomycin 500 mg/d, for 10 days). Given the prior presentation of an unstable sternum, we elected to remove three sternal wires. A vacuum-assisted closure (VAC) was placed along with Alginat to promote secondary wound healing. On the 26th postoperative day, the patient was discharged home with instructions to return for clinic three-times-per-week for wound care.
The incidence of sternal wound infection after cardiac surgery is reported to be 0.4-5%  and Staphylococcus aureus is the most common pathogen isolated from sternal wound infections after cardiac surgery as well as from bacteraemic blood cultures . An increasing trend in antibiotic resistance, with the appearance of progressively more cases of MRSA strain infections have been shown in epidemiological studies [6, 3]. Sternal infection with S. aureus is associated with high morbidity and mortality and carries a worse prognosis than that of other aetiologies .
Vancomycin remains the reference standard for the treatment of systemic infection caused by methicillin resistant Staphylococcus aureus (MRSA). However, there are many reasons for clinical failure of Vancomycin [8, 9], therefore the need for alternative therapies that target MRSA has become apparent. One alternative is Linezolid, because it has been shown that this antibiotic drug in retrospective evaluations of complicated skin and soft-tissue infections (SSTIs) caused by MRSA, compared with Vancomycin, is associated with significantly higher clinical cure rates and reduced lengths of hospitalization [10, 11]. Despite the apparent advantages of Linezolid in the treatment of MRSA infections, concerns about safety and costs of therapy often limit its use.
Daptomycin is a lipopeptide drug with bactericidal activity against MRSA in a concentration-dependent manner . The difference between Daptomycin and standard therapy in the treatment of MRSA infections was up to now not statistically significant, however Daptomycin has already been proven to be effective in the treatment of bacteremia and endocarditis caused by MRSA and several case reports about its effectiveness in the field of cardiac surgery exist in the literature [13–17]. Based on these observations, Daptomycin may offer a possible new treatment option for surgical management of MRSA sternal wound infection after cardiac surgery combined with surgical therapy.
In our case the patient was re-submitted to our hospital with generalized colonization and infection with MRSA. Standard therapy concerning antibiotic treatment has failed to eradicate the MRSA, so that we decided for an alternative antimicrobial strategy in the form of Daptomycin application. However, its longterm efficacy in cardiac surgery should be further evaluated in a controlled setting.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The project was supported by a grant from the Department of Thoracic Cardiovascular Surgery, University of Göttingen, Germany. The authors gratefully thank Mrs. D. Sitte for her expert assistance at wound treatment.
- National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control. 2002, 30: 458-75. 10.1067/mic.2002.130032.Google Scholar
- Kappstein I, Schulgen G, Fraedrich G, Schlosser V, Schumacher M, Daschner FD: Added hospital stay due to wound infections following cardiac surgery. Thorac Cardiovasc Surg. 1992, 40: 148-51. 10.1055/s-2007-1020134.View ArticlePubMedGoogle Scholar
- Sharma M, Berriel-Cass D, Baran J: Sternal surgical-site infection following coronary artery bypass graft: prevalence, microbiology, and complications during a 42-month period. Infect Control Hosp Epidemiol. 2004, 25: 468-71. 10.1086/502423.View ArticlePubMedGoogle Scholar
- Sjogren J, Malmsjo M, Gustafsson R, Ingemansson R: Poststernotomy mediastinitis: a review of conventional surgical treatments, vacuum assisted closure therapy and presentation of the Lund University Hospital mediastinitis algorithm. Eur J Cardiothorac Surg. 2006, 30: 898-905. 10.1016/j.ejcts.2006.09.020.View ArticlePubMedGoogle Scholar
- Poncelet AJ, Lengele B, Delaere B, Zech F, Glineur D, Funken JC, El Khoury G, Noirhomme P: Algorithm for primary closure in sternal wound infection: A single institution 10-year experience. Eur J Cardiothorac Surg. 2008, 33 (2): 232-38. 10.1016/j.ejcts.2007.11.016.View ArticlePubMedGoogle Scholar
- Fowler VG, Kaye KS, Simel DL, Cabell CH, McClachlan D, Smith PK, Levin S, Sexton DJ, Reller LB, Corey GR, Oddone EZ: Staphylococcus aureus bacteremia after median sternotomy: clinical utility of blood culture results in the identification of postoperative mediastinitis. Circulation. 2003, 108: 73-8. 10.1161/01.CIR.0000079105.65762.DB.View ArticlePubMedGoogle Scholar
- Gårdlund B, Bitkover CY, Vaage J: Postoperative Mediastinitis in cardiac surgery - microbiology and pathogenesis. Eur J Cardiothorac Surg. 2002, 21: 825-30. 10.1016/S1010-7940(02)00084-2.View ArticlePubMedGoogle Scholar
- Sakoulas G, Moellering RC, Eliopoulos GM: Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis. 2006, 42: 40-50. 10.1086/491713.View ArticleGoogle Scholar
- Robert J, Bismuth R, Jarlier V: Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother. 2006, 57: 506-10. 10.1093/jac/dki486.View ArticlePubMedGoogle Scholar
- Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C, Linezolid CSSTI Study Group: Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005, 49 (6): 2260-6. 10.1128/AAC.49.6.2260-2266.2005.View ArticlePubMedPubMed CentralGoogle Scholar
- Itani KM, Weigelt J, Li JZ, Duttagupta S: Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2005, 26 (6): 442-8. 10.1016/j.ijantimicag.2005.09.003.View ArticlePubMedGoogle Scholar
- Steenbergen JN, Alder J, Thorne GM, Tally FP: Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005, 55: 283-288. 10.1093/jac/dkh546.View ArticlePubMedGoogle Scholar
- Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE, S. aureus Endocarditis and Bacteremia Study Group: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006, 355 (7): 653-65. 10.1056/NEJMoa053783.View ArticlePubMedGoogle Scholar
- Furuya EY, Lowy FD: Antimicrobial strategies for the prevention and treatment of cardiovascular infections. Curr Opin Pharmacol. 2003, 3 (5): 464-9. 10.1016/j.coph.2003.05.004.View ArticlePubMedGoogle Scholar
- Marco F, de la Mària CG, Armero Y, Amat E, Soy D, Moreno A, del Río A, Almela M, Mestres CA, Gatell JM, Jiménez de Anta MT, Miró JM, Hospital Clinic Experimental Endocarditis Study Group: Daptomycin is effective in treatment of experimental. endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2008, 52 (7): 2538-43. 10.1128/AAC.00510-07.View ArticlePubMedPubMed CentralGoogle Scholar
- Schmitto JD, Popov AF, Sossalla ST, Coskun KO, Mokashi SA, Wintner A, Schoendube FA: Daptomycin for treatment of methicillin-resistant Staphylococcus epidermidis saphenectomy wound infection after coronary artery bypass graft operation (CABG): a case report. J Cardiothorac Surg. 2009, 4: 47-10.1186/1749-8090-4-47.View ArticlePubMedPubMed CentralGoogle Scholar
- Weis F, Beiras-Fernandez A, Kaczmarek I, Sodian R, Vicol C, Reichart B, Weis M: Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient. Ann Thorac Surg. 2007, 84 (1): 269-70. 10.1016/j.athoracsur.2007.02.001.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.